Diversified Trust Co Cuts Holdings in Bristol-Myers Squibb (NYSE:BMY)

Diversified Trust Co cut its holdings in Bristol-Myers Squibb (NYSE:BMY) by 23.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 46,155 shares of the biopharmaceutical company’s stock after selling 14,179 shares during the quarter. Diversified Trust Co’s holdings in Bristol-Myers Squibb were worth $2,611,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of BMY. Neville Rodie & Shaw Inc. grew its stake in shares of Bristol-Myers Squibb by 25.9% during the 4th quarter. Neville Rodie & Shaw Inc. now owns 50,589 shares of the biopharmaceutical company’s stock worth $2,861,000 after purchasing an additional 10,400 shares during the period. Boltwood Capital Management boosted its holdings in Bristol-Myers Squibb by 19.3% during the fourth quarter. Boltwood Capital Management now owns 4,705 shares of the biopharmaceutical company’s stock worth $266,000 after buying an additional 760 shares in the last quarter. CWA Asset Management Group LLC grew its position in Bristol-Myers Squibb by 27.5% during the fourth quarter. CWA Asset Management Group LLC now owns 111,149 shares of the biopharmaceutical company’s stock worth $6,287,000 after buying an additional 23,957 shares during the period. Pensionfund Sabic increased its holdings in Bristol-Myers Squibb by 32.8% in the fourth quarter. Pensionfund Sabic now owns 40,500 shares of the biopharmaceutical company’s stock valued at $2,291,000 after buying an additional 10,000 shares in the last quarter. Finally, First City Capital Management Inc. boosted its stake in shares of Bristol-Myers Squibb by 1.0% during the 4th quarter. First City Capital Management Inc. now owns 21,164 shares of the biopharmaceutical company’s stock worth $1,197,000 after acquiring an additional 219 shares in the last quarter. Institutional investors and hedge funds own 76.41% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the company. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $50.00 price objective on shares of Bristol-Myers Squibb in a report on Friday, October 18th. Morgan Stanley boosted their price objective on shares of Bristol-Myers Squibb from $36.00 to $39.00 and gave the stock an “underweight” rating in a research report on Tuesday, November 12th. Daiwa America upgraded shares of Bristol-Myers Squibb from a “hold” rating to a “strong-buy” rating in a report on Wednesday, November 13th. Sanford C. Bernstein initiated coverage on shares of Bristol-Myers Squibb in a report on Thursday, October 17th. They issued a “market perform” rating and a $56.00 price target on the stock. Finally, Jefferies Financial Group raised shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating and raised their price objective for the stock from $63.00 to $70.00 in a research note on Monday, December 16th. Two investment analysts have rated the stock with a sell rating, thirteen have issued a hold rating, three have given a buy rating and three have given a strong buy rating to the stock. According to MarketBeat.com, Bristol-Myers Squibb presently has a consensus rating of “Hold” and a consensus target price of $55.64.

Bristol-Myers Squibb Price Performance

Shares of NYSE BMY opened at $57.22 on Wednesday. The company has a debt-to-equity ratio of 2.83, a current ratio of 1.24 and a quick ratio of 1.09. Bristol-Myers Squibb has a 1-year low of $39.35 and a 1-year high of $61.08. The business has a 50-day moving average of $57.31 and a 200-day moving average of $51.26. The company has a market capitalization of $116.05 billion, a price-to-earnings ratio of -15.94, a PEG ratio of 15.20 and a beta of 0.45.

Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported $1.80 earnings per share for the quarter, beating analysts’ consensus estimates of $1.49 by $0.31. Bristol-Myers Squibb had a negative net margin of 15.30% and a positive return on equity of 11.94%. The company had revenue of $11.89 billion during the quarter, compared to analysts’ expectations of $11.26 billion. During the same period in the prior year, the company posted $2.00 EPS. The firm’s revenue for the quarter was up 8.4% on a year-over-year basis. On average, equities analysts anticipate that Bristol-Myers Squibb will post 0.93 EPS for the current fiscal year.

Bristol-Myers Squibb Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, February 3rd. Investors of record on Friday, January 3rd will be paid a $0.62 dividend. This represents a $2.48 dividend on an annualized basis and a dividend yield of 4.33%. The ex-dividend date is Friday, January 3rd. This is a positive change from Bristol-Myers Squibb’s previous quarterly dividend of $0.60. Bristol-Myers Squibb’s payout ratio is -69.08%.

Insider Activity at Bristol-Myers Squibb

In related news, SVP Phil M. Holzer sold 700 shares of the business’s stock in a transaction dated Monday, November 4th. The shares were sold at an average price of $55.62, for a total transaction of $38,934.00. Following the completion of the sale, the senior vice president now owns 11,760 shares of the company’s stock, valued at $654,091.20. This represents a 5.62 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Samit Hirawat bought 1,830 shares of the stock in a transaction dated Friday, November 1st. The shares were bought at an average cost of $54.67 per share, with a total value of $100,046.10. Following the completion of the acquisition, the executive vice president now directly owns 62,109 shares of the company’s stock, valued at approximately $3,395,499.03. The trade was a 3.04 % increase in their position. The disclosure for this purchase can be found here. 0.09% of the stock is currently owned by corporate insiders.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.